J. Litton Mark's Insider Trades & SAST Disclosures
J. Litton Mark's most recent trade in Athira Pharma Inc was a trade of 333,815 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 3, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern J. Litton Mark.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Athira Pharma Inc | Mark J. Litton | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 333,815 | 333,815 | - | - | Stock Option (Right to Buy) | |
| Athira Pharma Inc | Mark J. Litton | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 222,543 | 222,543 | - | - | Restricted Stock Units | |
| Athira Pharma Inc | Mark J. Litton | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 108,333 | 267,698 | - | 0 | Common Stock | |
| Athira Pharma Inc | Mark J. Litton | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 108,333 | 216,667 | - | - | Restricted Stock Units | |
| Athira Pharma Inc | Mark J. Litton | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 0.56 per share. | 31 Dec 2024 | 25,107 | 242,591 | - | 0.6 | 14,108 | Common Stock |
| Athira Pharma Inc | Mark J. Litton | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Oct 2024 | 325,000 | 325,000 | - | - | Stock Option (Right to Buy) | |
| Athira Pharma Inc | Mark J. Litton | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2024 | 20,000 | 164,397 | - | 0 | Common Stock | |
| Athira Pharma Inc | Mark J. Litton | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 0.57 per share. | 03 Sep 2024 | 5,032 | 159,365 | - | 0.6 | 2,848 | Common Stock |
| Athira Pharma Inc | Mark Litton J. | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 650,000 | 650,000 | - | - | Stock Option (Right to Buy) | |
| Athira Pharma Inc | Litton Mark J. | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 20,000 | 149,217 | - | 0 | Common Stock | |
| Athira Pharma Inc | Mark J. Litton | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 20,000 | 149,217 | - | 0 | Common Stock | |
| Athira Pharma Inc | Mark Litton J. | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 2.91 per share. | 04 Jan 2024 | 4,820 | 144,397 | - | 2.9 | 14,026 | Common Stock |
| Athira Pharma Inc | J. Litton Mark | Director, CEO | Sale of securities on an exchange or to another person at price $ 2.91 per share. | 04 Jan 2024 | 4,820 | 144,397 | - | 2.9 | 14,026 | Common Stock |
| Athira Pharma Inc | Mark J. Litton | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2023 | 425,000 | 425,000 | - | - | Stock Option (Right to Buy) | |
| Athira Pharma Inc | Mark J. Litton | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 2.74 per share. | 27 Jan 2023 | 662 | 129,217 | - | 2.7 | 1,814 | Common Stock |
| Athira Pharma Inc | Mark J. Litton | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2022 | 400,000 | 400,000 | - | - | Stock Option (Right to Buy) | |
| Athira Pharma Inc | Mark J. Litton | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 12.51 per share. | 27 Jan 2022 | 885 | 115,758 | - | 12.5 | 11,071 | Common Stock |
| Athira Pharma Inc | Mark J. Litton | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2021 | 50,440 | 100,880 | - | - | Stock Option (Right to Buy) | |
| Athira Pharma Inc | Mark J. Litton | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.35 per share. | 17 Aug 2021 | 50,440 | 114,873 | - | 1.4 | 68,094 | Common Stock |
| Athira Pharma Inc | Mark J. Litton | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 14.45 per share. | 17 Aug 2021 | 867 | 64,433 | - | 14.4 | 12,528 | Common Stock |
| Athira Pharma Inc | Mark J. Litton | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2021 | 85,000 | 85,000 | - | - | Stock Option (Right to Buy) | |
| Athira Pharma Inc | Mark J. Litton | Chief Operating Officer | 22 Sep 2020 | 13,126 | 0 | - | - | Series B Preferred Stock | ||
| Athira Pharma Inc | Mark J. Litton | Chief Operating Officer | 22 Sep 2020 | 13,126 | 63,566 | - | 0 | Common Stock | ||
| Athira Pharma Inc | Mark J. Litton | Chief Operating Officer | 22 Sep 2020 | 6,563 | 0 | - | - | Series B-1 Preferred Stock | ||
| Athira Pharma Inc | Mark J. Litton | Chief Operating Officer | 22 Sep 2020 | 6,563 | 6,563 | - | 0 | Common Stock | ||
| Athira Pharma Inc | Mark J. Litton | Chief Operating Officer | 22 Sep 2020 | 6,563 | 6,563 | - | 0 | Common Stock | ||
| Athira Pharma Inc | Mark J. Litton | Chief Operating Officer | 22 Sep 2020 | 6,563 | 6,563 | - | 0 | Common Stock | ||
| Athira Pharma Inc | Mark J. Litton | Chief Operating Officer | 22 Sep 2020 | 6,563 | 0 | - | - | Series B-1 Preferred Stock | ||
| Athira Pharma Inc | Mark J. Litton | Chief Operating Officer | 22 Sep 2020 | 6,563 | 0 | - | - | Series B-1 Preferred Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges